A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Pfizer
Pfizer
Scripps Translational Science Institute
Thomas Jefferson University
Altor BioScience
Altor BioScience
Novartis
Teva Branded Pharmaceutical Products R&D, Inc.
Amgen
GlaxoSmithKline
AbbVie
Merck Sharp & Dohme LLC
Icahn School of Medicine at Mount Sinai
Novartis
GlaxoSmithKline
GlaxoSmithKline
InSightec
Masonic Cancer Center, University of Minnesota
University of Arizona
Amgen
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
University of Kansas Medical Center
Genentech, Inc.
Leap Therapeutics, Inc.
University of Utah
Sandoz
University of Arkansas
University of Arkansas
Oncotherapeutics
Janssen-Cilag G.m.b.H
INSYS Therapeutics Inc
Amgen
Fred Hutchinson Cancer Center
Emory University